Rheumatology
Switching from Mepolizumab to Benralizumab in EGPA: A Promising Alternative for Persistent Respiratory Symptoms
In EGPA patients unresponsive to mepolizumab, switching to benralizumab improves lung function, reduces glucocorticoid use, and shows a favorable safety profile, suggesting its potential as an effective alternative treatment.
